Tanguler Tolga — SEC Form 4 filings
SEC reporting owner CIK 1849458. 18 Form 4 filings on record with FilingPulse; latest filed 2026-06-29.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-02-20 to 2026-06-29. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 105 legs across 13 filings — 19,219 shares, $6,455,916 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: sale of 1,959 shares @ $310.08 ($607,448) in ALNYLAM PHARMACEUTICALS, INC., filed 2026-02-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Commercial Officer | 15 | — | 105 legs · 19,219 sh · $6,455,916 | 19 |
| Lexeo Therapeutics, Inc. (LXEO) | Director | 3 | — | — | 3 |
Form 4 filings — Tanguler Tolga
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-29 | 4 | Lexeo Therapeutics, Inc. (LXEO) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Sale (S): 106 @ $319.03 · Sale (S): 102 @ $320.01 · Sale (S): 215 @ $320.81 · Sale (S): 289 @ $321.82 · Sale (S): 350 @ $323.01 · Sale (S): 767 @ $323.84 · +2 more | EDGAR |
| 2026-03-04 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,769 @ $0 · Sale (S): 47 @ $323.62 · Sale (S): 90 @ $324.65 · Sale (S): 258 @ $325.63 · Sale (S): 392 @ $326.81 · Sale (S): 329 @ $327.67 · +6 more | EDGAR |
| 2026-03-02 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,666 @ $0 · Option exercise (M): 1,666 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,000 @ $0 · Sale (S): 1,959 @ $310.08 | EDGAR |
| 2026-01-14 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,800 @ $0 · Sale (S): 39 @ $353.95 · Sale (S): 42 @ $355.16 · Sale (S): 41 @ $356.09 · Sale (S): 96 @ $357.17 · Sale (S): 123 @ $358.18 · +16 more | EDGAR |
| 2025-10-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 2,851 @ $0 · Sale (S): 55 @ $446.53 · Sale (S): 27 @ $447.92 · Sale (S): 86 @ $448.77 · Sale (S): 119 @ $449.79 · Sale (S): 260 @ $450.81 · +7 more | EDGAR |
| 2025-09-02 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Sale (S): 195 @ $445.53 · Sale (S): 899 @ $446.98 · Sale (S): 1,289 @ $448.05 · Sale (S): 681 @ $449.54 · Sale (S): 266 @ $451.52 · Sale (S): 144 @ $452.49 | EDGAR |
| 2025-08-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 2,851 @ $0 · Sale (S): 39 @ $447.98 · Sale (S): 90 @ $449.92 · Sale (S): 39 @ $450.92 · Sale (S): 103 @ $451.99 · Sale (S): 329 @ $452.96 · +3 more | EDGAR |
| 2025-06-30 | 4 | Lexeo Therapeutics, Inc. (LXEO) | Grant/award (A): 14,583 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 14,137 @ $0 · Sale (S): 131 @ $242.37 · Sale (S): 142 @ $243.36 · Sale (S): 96 @ $244.41 · Sale (S): 70 @ $245.26 · Sale (S): 29 @ $246.18 · +2 more | EDGAR |
| 2025-03-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,667 @ $0 · Sale (S): 28 @ $236.51 · Sale (S): 22 @ $238.33 · Sale (S): 23 @ $239.18 · Sale (S): 50 @ $240.32 · Sale (S): 82 @ $241.51 · +4 more | EDGAR |
| 2024-11-27 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,000 @ $0 · Sale (S): 26 @ $247.77 · Sale (S): 215 @ $249.60 · Sale (S): 318 @ $250.68 · Sale (S): 826 @ $251.42 · Sale (S): 84 @ $252.27 | EDGAR |
| 2024-11-13 | 4 | Lexeo Therapeutics, Inc. (LXEO) | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2024-06-26 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,278 @ $0 · Sale (S): 59 @ $221.71 · Sale (S): 13 @ $224.17 · Sale (S): 18 @ $225.55 · Sale (S): 34 @ $226.82 · Sale (S): 129 @ $228.30 · +7 more | EDGAR |
| 2024-03-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,751 @ $0 · Grant/award (A): 9,279 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,667 @ $0 · Sale (S): 216 @ $154.54 · Sale (S): 170 @ $155.45 · Sale (S): 100 @ $156.38 · Sale (S): 14 @ $157.30 · Sale (S): 1 @ $158.09 · +1 more | EDGAR |
| 2024-02-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,278 @ $0 · Sale (S): 369 @ $147.50 · Sale (S): 519 @ $148.24 · Sale (S): 121 @ $149.03 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1849458 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →